---
title: "Guggenheim Sticks to Its Buy Rating for Urogen Pharma (URGN)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274510891.md"
description: "Guggenheim analyst Michael Schmidt has reaffirmed a Buy rating for Urogen Pharma (URGN) with a price target of $32.00. Schmidt, a 5-star analyst with a 28.1% average return and 57.07% success rate, focuses on the Healthcare sector. The current analyst consensus for Urogen Pharma is a Strong Buy, with an average price target of $38.60."
datetime: "2026-02-02T11:56:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274510891.md)
  - [en](https://longbridge.com/en/news/274510891.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274510891.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/274510891.md) | [繁體中文](https://longbridge.com/zh-HK/news/274510891.md)


# Guggenheim Sticks to Its Buy Rating for Urogen Pharma (URGN)

Guggenheim analyst Michael Schmidt maintained a Buy rating on Urogen Pharma yesterday and set a price target of $32.00.

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Schmidt is a 5-star analyst with an average return of 28.1% and a 57.07% success rate. Schmidt covers the Healthcare sector, focusing on stocks such as Genmab, Arcellx Inc, and Incyte.

Currently, the analyst consensus on Urogen Pharma is a Strong Buy with an average price target of $38.60.

### Related Stocks

- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [iShares Global Healthcare ETF (IXJ.US)](https://longbridge.com/en/quote/IXJ.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [UroGen Pharma Ltd. (URGN.US)](https://longbridge.com/en/quote/URGN.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)

## Related News & Research

- [13:06 ETHall Render Represents Centurion Foundation in Rhode Island Hospital Acquisition, Preserving Essential Health Care Services](https://longbridge.com/en/news/278427087.md)
- [Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spend](https://longbridge.com/en/news/279032442.md)
- [Spruce Biosciences 2025 net loss narrows, secures $50 mln funding](https://longbridge.com/en/news/278380208.md)
- [Clene 2025 net loss narrows as expenses fall](https://longbridge.com/en/news/278880252.md)
- [Incannex Healthcare Prices $10 Mln Potential Offering Of Shares And Warrants; Stock Down](https://longbridge.com/en/news/278896600.md)